Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Gross Margin (2016 - 2025)

Vanda Pharmaceuticals' Gross Margin history spans 13 years, with the latest figure at 93.3% for Q4 2025.

  • For Q4 2025, Gross Margin fell 183.0% year-over-year to 93.3%; the TTM value through Dec 2025 reached 93.96%, down 34.0%, while the annual FY2025 figure was 93.96%, 34.0% down from the prior year.
  • Gross Margin for Q4 2025 was 93.3% at Vanda Pharmaceuticals, down from 94.75% in the prior quarter.
  • Across five years, Gross Margin topped out at 95.13% in Q4 2024 and bottomed at 90.3% in Q3 2021.
  • The 5-year median for Gross Margin is 92.36% (2023), against an average of 92.29%.
  • The largest annual shift saw Gross Margin soared 277bps in 2024 before it tumbled -183bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 90.83% in 2021, then dropped by -1bps to 90.33% in 2022, then rose by 2bps to 92.36% in 2023, then increased by 3bps to 95.13% in 2024, then decreased by -2bps to 93.3% in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Gross Margin are 93.3% (Q4 2025), 94.75% (Q3 2025), and 94.8% (Q2 2025).